PMID- 21600018
OWN - NLM
STAT- MEDLINE
DCOM- 20110927
LR  - 20220408
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 6
DP  - 2011 May 21
TI  - Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic 
      colorectal cancer.
PG  - 52
LID - 10.1186/1748-717X-6-52 [doi]
AB  - BACKGROUND: To evaluate the palliative role of radiotherapy (RT) and define the 
      effectiveness of chemotherapy combined with palliative RT (CCRT) in patients with 
      a symptomatic pelvic mass of metastatic colorectal cancer. METHODS: From August 
      1995 to December 2007, 80 patients with a symptomatic pelvic mass of metastatic 
      colorectal cancer were treated with palliative RT at Samsung Medical Center. 
      Initial presenting symptoms were pain (68 cases), bleeding (18 cases), and 
      obstruction (nine cases). The pelvic mass originated from rectal cancer in 58 
      patients (73%) and from colon cancer in 22 patients (27%). Initially 72 patients 
      (90%) were treated with surgery, including 64 complete local excisions; 77% in 
      colon cancer and 81% in rectal cancer. The total RT dose ranged 8-60 Gy (median: 
      36 Gy) with 1.8-8 Gy per fraction. When the alpha/beta for the tumor was assumed to be 
      10 Gy for the biologically equivalent dose (BED), the median RT dose was 46.8 
      Gy10 (14.4-78). Twenty one patients (26%) were treated with CCRT. Symptom 
      palliation was assessed one month after the completion of RT. RESULTS: Symptom 
      palliation was achieved in 80% of the cases. During the median follow-up period 
      of five months (1-44 months), 45% of the cases experienced reappearance of 
      symptoms; the median symptom control duration was five months. Median survival 
      after RT was six months. On univariate analysis, the only significant prognostic 
      factor for symptom control duration was BED >/=40 Gy10 (p < 0.05), and CCRT was a 
      marginally significant factor (p = 0.0644). On multivariate analysis, BED and 
      CCRT were significant prognostic factors for symptom control duration (p < 0.05). 
      CONCLUSIONS: RT was an effective palliation method in patients with a symptomatic 
      pelvic mass of metastatic colorectal cancer. For improvement of symptom control 
      rate and duration, a BED >/= 40 Gy10 is recommended when possible. Considering the 
      low morbidity and improved symptom palliation, CCRT might be considered in 
      patients with good performance status.
FAU - Bae, Sun Hyun
AU  - Bae SH
AD  - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Korea.
FAU - Park, Won
AU  - Park W
FAU - Choi, Doo Ho
AU  - Choi DH
FAU - Nam, Heerim
AU  - Nam H
FAU - Kang, Won Ki
AU  - Kang WK
FAU - Park, Young Suk
AU  - Park YS
FAU - Park, Joon Oh
AU  - Park JO
FAU - Chun, Ho Kyung
AU  - Chun HK
FAU - Lee, Woo Yong
AU  - Lee WY
FAU - Yun, Seong Hyeon
AU  - Yun SH
FAU - Kim, Hee Cheol
AU  - Kim HC
LA  - eng
PT  - Journal Article
DEP - 20110521
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*radiotherapy
MH  - Dose-Response Relationship, Radiation
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Palliative Care/*methods
MH  - Pelvic Neoplasms/*radiotherapy
MH  - Prognosis
MH  - Treatment Outcome
PMC - PMC3130661
EDAT- 2011/05/24 06:00
MHDA- 2011/09/29 06:00
PMCR- 2011/05/21
CRDT- 2011/05/24 06:00
PHST- 2011/01/29 00:00 [received]
PHST- 2011/05/21 00:00 [accepted]
PHST- 2011/05/24 06:00 [entrez]
PHST- 2011/05/24 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
PHST- 2011/05/21 00:00 [pmc-release]
AID - 1748-717X-6-52 [pii]
AID - 10.1186/1748-717X-6-52 [doi]
PST - epublish
SO  - Radiat Oncol. 2011 May 21;6:52. doi: 10.1186/1748-717X-6-52.